Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (71)
  2. Journal Article (32)
  3. Research Letter (6)
  4. Correspondence (4)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (119)
  2. Center for Hematologic Malignancies (119)
  3. Department of Medicine (119)
  4. Hematologic Malignancies, Division of (119)
  5. Hematology-Oncology Fellows (119)
  6. Weinberg Fellows (119)

More Groups

People
  1. Martin Tallman (49)
  2. Eytan Stein (43)
  3. Christopher Famulare (38)
  4. Andriy Derkach (22)
  5. Ross Levine (21)
  6. Jan Bewersdorf (20)

More People

Years
  1. 2025 (6)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (63)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. British Journal of Haematology (4)

More Publications

Publishers
  1. American Society of Hematology (68)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (6)
  5. Elsevier Inc. (4)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (119)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
    Research Letter

    King, A. C.; Weis, T. M.; Derkach, A.; Ball, S.; Pandey, M.; Mauro, M. J.; Goldberg, A. D.; Stahl, M.; Famulare, C.; Tallman, M. S.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Real-world management of patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Vachhani, P.; Wolach, O.; Garcia, J. S.; Zeidner, J. F.; Talati, C.; Pollyea, D. A.; Lai, C.; Moshe, Y.; Abedin, S.; Lavie, D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis
    Meeting Abstract

    Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Risks for hospitalization and death among patients with blood disorders from the ASH RC COVID-19 Registry for Hematology
    Meeting Abstract

    Hicks, L. K.; Redd, R. A.; Anderson, K. C.; Desai, P.; Dolan, B.; Goldberg, A. D.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Sehn, L. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I and expansion study of eprenetapopt (APR-246) in combination with venetoclax (VEN) and azacitidine (AZA) in TP53-mutant acute myeloid leukemia (AML)
    Meeting Abstract

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P.; Altman, J. K.; Cherry, M.; Tomlinson, B.; Chandhok, N.; Zhang, H.; Rastgoo, N.; Benbatoul, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia
    Meeting Abstract

    Grenet, J.; Jain, A. G.; Burkart, M.; Waksal, J.; Famulare, C.; Numan, Y.; Stahl, M.; Mckinnell, Z.; Ball, B.; Ma, X.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) data hub
    Meeting Abstract

    Desai, P.; Goldberg, A. D.; Anderson, K. C.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Redd, R. A.; Roboz, G. J.; Sehn, L. H.; Sekeres, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Multicenter analysis of treatment and outcomes for patient with TP53 mutated AML in the era of novel therapies; Significant impact of allogeneic stem cell transplantation on survival
    Meeting Abstract

    Badar, T.; Litzow, M. R.; Shallis, R. M.; Bewersdorf, J. P.; Saliba, A.; sacchi De Camargo Correia, G.; Stahl, M.; Goldberg, A. D.; Atallah, E. L.; Foran, J. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save